Diamyd Medical and UCLA advances therapeutic development

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diamyd Medical and UCLA advances therapeutic development for type 1 diabetes

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that Diamyd Medical has agreed to further advance its Antigen Based Technology together with researchers at the University of California, Los Angeles (UCLA). Strong synergistic effects have earlier been reported in an animal model receiving GABA in combination with either GAD65 or proinsulin. This new preclinical study will evaluate if GABA in combination with both autoantigens improves efficacy even further. Diamyd Medical licenses exclusive rights from UCLA for the therapeutic use of GABA alone or in combination with antigens for the treatment of diabetes and other inflammation-related conditions. “The new study is an important component in evaluating a next-generation antigen -specific immunotherapy for autoimmune diabetes based on our licensed and patented technologies,” says Ulf Hannelius, President & CEO of Diamyd Medical. Previously published results show that GABA in combination with either GAD65 or proinsulin result in strong synergistic effects on enhancing beta cell health and reversing hyperglycemia in preclinical type 1 diabetes mouse models. A first clinical study where GABA is combined with the diabetes vaccine Diamyd® is on -going at the University of Alabama, Birmingham. About Diamyd Medical Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd®. Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. For further information, please contact: Ulf Hannelius, President and CEO Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 181

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 122

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 203

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: C3.ai Faces Class Action Over Financial Disclosures

Updated Category News Views 198

Investors Alert Regarding Class Action Lawsuit Against C3.ai NEW YORK and NEW ORLEANS — Investors of C3.ai, Inc. are encouraged to act swiftly regarding a class action lawsuit. If you have experienced losses exceeding $100,000 and purchased the company’s securities between February 26, 2025, and August 8, 2025, you may be eligible to participate as lead plaintiff in...

Continue Reading
XCMG's Global Expansion: Building Bridges Down Under and Beyond

Updated Category News Views 58

Trade Missions and Machinery: A Strategic Move Trade winds are blowing from Xuzhou to Jakarta and Sydney, with XCMG Group's top brass spearheading efforts. Chairman Yang Dongsheng and his band of delegates are making big waves, strengthening ties with Indonesia and Australia. Now, any seasoned trader will tell you to keep an eye on these moves—it's all about setting the...

Continue Reading
Local Expertise Wins in Luxury Real Estate Market

Updated Category News Views 48

Why Local Expertise Still Matters Technology has transformed how we shop for real estate, but when it comes to luxury, Jud Whitlock isn't buying the idea that local knowledge doesn't matter. This guy's been around the block, and in a recent HelloNation piece, he dropped some truths that every global buyer and seller ought to take to heart. If you're thinking a snazzy app...

Continue Reading
Hewlett Packard Enterprise's Bold Move with AI Day and Juniper

Updated Category News Views 90

Hewlett Packard Enterprise Sets the Stage for AI Day with Exciting Developments Hewlett Packard Enterprise Co (HPE) is making headlines as it sets out on an ambitious path by acquiring Juniper Networks for a significant $14 billion. This pivotal acquisition underscores the company's commitment to advancing its position in the technology market, particularly in the realms...

Continue Reading
BRT Realty Trust Achieves 52-Week Milestone: Here’s What It Means

Updated Category News Views 153

BRT Realty Trust: A Closer Look at Recent Success Recently, BRT Realty Trust (NYSE: BRT) made headlines by hitting a remarkable 52-week high, with shares trading at $20.12. This achievement signifies a strong upward trend for the real estate investment trust, particularly known for its focus on multi-family properties. In the past year alone, BRT Realty Trust has seen its...

Continue Reading